VEGFA and neoplastic syndrome: Levalbuterol and other beta2-adrenergic-related agents inhibited the release of eotaxin, VEGFa, and IL-13 from mice engrafted with human peripheral blood monocyte cultures in a Jackson Laboratory assay, supporting predictions of similar gene-expression mechanisms and potential translation to inflammatory pathologies and neoplastic syndromes.